112 related articles for article (PubMed ID: 28720529)
1. Population Characteristics and Progressive Disability in Neurofibromatosis Type 2.
Iwatate K; Yokoo T; Iwatate E; Ichikawa M; Sato T; Fujii M; Sakuma J; Saito K
World Neurosurg; 2017 Oct; 106():653-660. PubMed ID: 28720529
[TBL] [Abstract][Full Text] [Related]
2. Characterization of early onset neurofibromatosis type 2.
Matsuo M; Ohno K; Ohtsuka F
Brain Dev; 2014 Feb; 36(2):148-52. PubMed ID: 23414620
[TBL] [Abstract][Full Text] [Related]
3. Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients.
Ruggieri M; Iannetti P; Polizzi A; La Mantia I; Spalice A; Giliberto O; Platania N; Gabriele AL; Albanese V; Pavone L
Neuropediatrics; 2005 Feb; 36(1):21-34. PubMed ID: 15776319
[TBL] [Abstract][Full Text] [Related]
4. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium.
Fisher LM; Doherty JK; Lev MH; Slattery WH
Otol Neurotol; 2009 Sep; 30(6):835-41. PubMed ID: 19704365
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2.
Sun S; Liu A
J Neurosurg; 2014 Dec; 121 Suppl():143-9. PubMed ID: 25434947
[TBL] [Abstract][Full Text] [Related]
6. Unilateral vestibular schwannoma with other neurofibromatosis type 2-related tumors: clinical and molecular study of a unique phenotype.
Aghi M; Kluwe L; Webster MT; Jacoby LB; Barker FG; Ojemann RG; Mautner VF; MacCollin M
J Neurosurg; 2006 Feb; 104(2):201-7. PubMed ID: 16509493
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value and management of spinal tumors in neurofibromatosis type 2 patients.
Aboukais R; Baroncini M; Zairi F; Bonne NX; Schapira S; Vincent C; Lejeune JP
Acta Neurochir (Wien); 2013 May; 155(5):771-7. PubMed ID: 23381342
[TBL] [Abstract][Full Text] [Related]
8. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity.
Parry DM; Eldridge R; Kaiser-Kupfer MI; Bouzas EA; Pikus A; Patronas N
Am J Med Genet; 1994 Oct; 52(4):450-61. PubMed ID: 7747758
[TBL] [Abstract][Full Text] [Related]
9. Predictors of vestibular schwannoma growth in patients with neurofibromatosis Type 2.
Baser ME; Makariou EV; Parry DM
J Neurosurg; 2002 Feb; 96(2):217-22. PubMed ID: 11838793
[TBL] [Abstract][Full Text] [Related]
10. Intracranial meningiomas and neurofibromatosis type 2.
Aboukais R; Zairi F; Baroncini M; Bonne NX; Schapira S; Vincent C; Lejeune JP
Acta Neurochir (Wien); 2013 Jun; 155(6):997-1001; discussion 1001. PubMed ID: 23558725
[TBL] [Abstract][Full Text] [Related]
11. Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution.
Li P; Zhao F; Zhang J; Wang Z; Wang X; Wang B; Yang Z; Yang J; Gao Z; Liu P
J Neurosurg Spine; 2016 Jan; 24(1):145-54. PubMed ID: 26407091
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis of sporadic neurofibromatosis type 2 in the paediatric population.
Anand G; Vasallo G; Spanou M; Thomas S; Pike M; Kariyawasam DS; Mehta S; Parry A; Durie-Gair J; Nicholson J; Lascelles K; Everett V; Gibbon FM; Jarvis N; Elston J; Evans DG; Halliday D
Arch Dis Child; 2018 May; 103(5):463-469. PubMed ID: 29535107
[TBL] [Abstract][Full Text] [Related]
13. Clinical features of newly developed NF2 intracranial meningiomas through comparative analysis of pediatric and adult patients.
Li P; Wu T; Wang Y; Zhao F; Wang Z; Wang X; Wang B; Yang Z; Liu P
Clin Neurol Neurosurg; 2020 Jul; 194():105799. PubMed ID: 32229353
[TBL] [Abstract][Full Text] [Related]
14. Age at symptom onset and long-term survival in patients with neurofibromatosis Type 2.
Otsuka G; Saito K; Nagatani T; Yoshida J
J Neurosurg; 2003 Sep; 99(3):480-3. PubMed ID: 12959433
[TBL] [Abstract][Full Text] [Related]
15. Genetic Severity Score predicts clinical phenotype in NF2.
Halliday D; Emmanouil B; Pretorius P; MacKeith S; Painter S; Tomkins H; Evans DG; Parry A
J Med Genet; 2017 Oct; 54(10):657-664. PubMed ID: 28848060
[TBL] [Abstract][Full Text] [Related]
16. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity.
Evans DG; Huson SM; Donnai D; Neary W; Blair V; Teare D; Newton V; Strachan T; Ramsden R; Harris R
J Med Genet; 1992 Dec; 29(12):841-6. PubMed ID: 1479598
[TBL] [Abstract][Full Text] [Related]
17. Linear accelerator-based stereotactic radiosurgery for bilateral vestibular schwannomas in patients with neurofibromatosis type 2.
Meijer OW; Vandertop WP; Lagerwaard FJ; Slotman BJ
Neurosurgery; 2008 May; 62(5 Suppl):A37-42; discussion A42-3. PubMed ID: 18580779
[TBL] [Abstract][Full Text] [Related]
18. Spinal tumors in neurofibromatosis type 2. Is emerging knowledge of genotype predictive of natural history?
Dow G; Biggs N; Evans G; Gillespie J; Ramsden R; King A
J Neurosurg Spine; 2005 May; 2(5):574-9. PubMed ID: 15945431
[TBL] [Abstract][Full Text] [Related]
19. Progression of hearing loss in neurofibromatosis type 2 according to genetic severity.
Emmanouil B; Houston R; May A; Ramsden JD; Hanemann CO; Halliday D; Parry A; Mackeith S
Laryngoscope; 2019 Apr; 129(4):974-980. PubMed ID: 30456886
[TBL] [Abstract][Full Text] [Related]
20. Loss of social independence in patients with neurofibromatosis type 2: a follow-up study using a national registry in Japan.
Okoshi H; Yamauchi T; Suka M; Yanagisawa H; Fujii M; Nishigori C
Environ Health Prev Med; 2023; 28():46. PubMed ID: 37599081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
